MedElevator Войти в исследования
← Поиск публикаций

DOI 10.23736/s2784-8671.26.08303-9

Медицинская библиотека · Italian journal of dermatology and venereology · 2026

Open-label, uncontrolled clinical investigation of the performance and safety of a foam containing a hyaluronic acid-derived biopolymer and humectants for management of dermatitis in adults.

Persechino Severino, Manni Martina, Innocenti Silvia, DI Vico Francesca, DI Guida Adriana, Abategiovanni Luisa, Capalbo Alessandro, Gagliostro Nazareno, Ambrosio Luca, Napolitano Maddalena

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Atopic (AD) and contact (CD) dermatitis can interfere with everyday function. Non-prescription topical formulations can aid AD/CD symptom relief and alleviate exacerbation. In this post-marketing clinical investigation, performance and safety of a foam containing sodium butyroyl/formoyl hyaluronate, glycerol and panthenol was investigated.

METHODS

This multicenter, open-label, uncontrolled, post-marketing clinical follow-up investigation included 37 adults with mild-to-moderate AD, irritant CD (ICD) or allergic CD (ACD). The foam was applied twice-a-day to affected areas for 42 days and assessed on Days 14, 28 and 42 using the Investigators Global Assessment score (ICA; rated 0-5); the Eczema Area and Severity Index (EASI); the Dermatology Life Quality Index (DLQI); visual analogue scales (VAS) for pruritus, scratching, pain and burning; investigator's global evaluation of performance and participant overall treatment acceptability. Primary endpoint was IGA score change from baseline to Day 28. Success was prespecified as an IGA score decrease ≥1.

RESULTS

At Day 28, mean IGA score decreased from baseline by 1.11 (standard deviation 0.68) with treatment success in 88.6% of participants (P<0.0001). At Days 14/42, 52.8%/94.3% (P<0.0001) showed an improved IGA. Progressive improvements were shown in EASI, VAS and DLQI scores to Day 42, significant at each timepoint (P<0.001). For participant and investigator performance evaluation, 94.3% reported improvement. Most participants rated the foam's acceptability as "very much satisfied" or "satisfied." The foam was generally well-tolerated.

CONCLUSIONS

Use of a foam containing sodium butyroyl/formoyl hyaluronate, glycerol and panthenol led to significant alleviation of AD, ICD or ACD and decreased associated quality of life impacts.

Для цитирования: Persechino Severino, Manni Martina, Innocenti Silvia, DI Vico Francesca, DI Guida Adriana, Abategiovanni Luisa, Capalbo Alessandro, Gagliostro Nazareno, Ambrosio Luca, Napolitano Maddalena. Open-label, uncontrolled clinical investigation of the performance and safety of a foam containing a hyaluronic acid-derived biopolymer and humectants for management of dermatitis in adults.. Italian journal of dermatology and venereology. 2026. DOI: 10.23736/s2784-8671.26.08303-9.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.